Performance summary Business description Business review Governance Financial statements Additional information Notes to the consolidated 137 fi financial statements Cash fl ow and net investment hedges The following table shows the contractual maturities of designated transaction, cross currency interest rate swaps and derivative net investment hedging instruments at 30 June 2009 and 30 June 2008: Foreign currency amount Percentage of total Purchase Sell Total US dollar Euro Year ending million million million % % 30 June 2009 Transaction 1,177 2,457 3,634 46 36 2010 Transaction 499 1,317 1,816 48 37 2011 Total transaction hedges 1,676 3,774 5,450 47 37 2010-2011 Cross currency interest rate swaps 364 364 100 2017 Cross currency interest rate swaps 364 364 100 2037 Total cross currency interest rate swaps 728 728 100 2017-2037 Net investment hedging instruments 2,938 1,594 4,532 60 17 2009 2008 Transaction 1,269 2,639 3,908 39 38 2009 Transaction 448 1,031 1,479 44 40 2010 Total transaction hedges 1,717 3,670 5,387 40 38 2009-2010 Cross currency interest rate swaps 302 302 100 2017 Cross currency interest rate swaps 302 302 100 2037 Total cross currency interest rate swaps 604 604 100 2017-2037 Net investment hedging instruments 2,912 2,370 5,282 58 21 2009 g Credit risk Details of the groups credit risk policies and exposures are presented under Risk management in the Business review.
Cash and cash equivalents comprise cash in hand and deposits which are readily convertible to known amounts of cash and which are subject to insignifi cant risk of changes in value and have an original maturity of three months or less at acquisition including money market deposits, commercial paper and investments.
At 30 June 2009, approximately 11% and 46% of the groups cash and cash equivalents of 914 million were invested with counterparties based in the United Kingdom and in the United States, respectively.
At 30 June 2009, approximately 16% and 20% of the groups trade receivables of 1,568 million were due from counterparties based in the United Kingdom and in the United States, respectively.
Trade and other payables 2009 2008 Current Non-current Current Non-current liabilities liabilities liabilities liabilities million million million million Trade payables 655 664 Tax and social security excluding income tax 293 311 1 Other payables 559 30 485 33 Accruals and deferred income 666 683 2,173 30 2,143 34 24.
Provisions Thalidomide Onerous Vacant Trust contracts Restructuring properties Other Total million million million million million million At 30 June 2008 141 79 78 19 84 401 Exchange diff erences 17 6 11 34 Provisions charged during the year 70 5 45 120 Provisions used during the year 8 19 5 8 51 91 Acquisition of businesses 5 5 Unwinding of discounts 10 5 1 1 17 At 30 June 2009 143 82 150 17 94 486 Included in current liabilities 9 14 103 6 40 172 Included in non-current liabilities 134 68 47 11 54 314 143 82 150 17 94 486 Provisions by their nature are subject to uncertainties with respect to the timing and outcomes of future events.
a The Thalidomide Trust provision was established in the year ended 30 June 2005 in respect of the discounted value of the groups commitment to the Thalidomide Trust, and will be utilised over the period of the commitment up to 2037.
